- Home
- TLSI vs CCIF Comparison
TLSI vs CCIF Comparison
Compare TLSI & CCIF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- CCIF
- Stock Information
- Founded
- TLSI 2010
- CCIF 2011
- Country
- TLSI United States
- CCIF United States
- Employees
- TLSI N/A
- CCIF N/A
- Industry
- TLSI Medical Specialities
- CCIF Finance/Investors Services
- Sector
- TLSI Health Care
- CCIF Finance
- Exchange
- TLSI Nasdaq
- CCIF Nasdaq
- Market Cap
- TLSI 150.0M
- CCIF 121.4M
- IPO Year
- TLSI N/A
- CCIF N/A
- Fundamental
- Price
- TLSI $4.80
- CCIF $5.83
- Analyst Decision
- TLSI Strong Buy
- CCIF
- Analyst Count
- TLSI 5
- CCIF 0
- Target Price
- TLSI $10.90
- CCIF N/A
- AVG Volume (30 Days)
- TLSI 95.6K
- CCIF 76.9K
- Earning Date
- TLSI 11-13-2025
- CCIF 01-01-0001
- Dividend Yield
- TLSI N/A
- CCIF 25.90%
- EPS Growth
- TLSI N/A
- CCIF N/A
- EPS
- TLSI N/A
- CCIF N/A
- Revenue
- TLSI $35,990,000.00
- CCIF N/A
- Revenue This Year
- TLSI $56.79
- CCIF N/A
- Revenue Next Year
- TLSI $54.15
- CCIF N/A
- P/E Ratio
- TLSI N/A
- CCIF N/A
- Revenue Growth
- TLSI 45.50
- CCIF N/A
- 52 Week Low
- TLSI $3.42
- CCIF $7.43
- 52 Week High
- TLSI $5.88
- CCIF $10.16
- Technical
- Relative Strength Index (RSI)
- TLSI 51.02
- CCIF 56.48
- Support Level
- TLSI $4.41
- CCIF $5.65
- Resistance Level
- TLSI $4.93
- CCIF $5.91
- Average True Range (ATR)
- TLSI 0.28
- CCIF 0.12
- MACD
- TLSI -0.05
- CCIF 0.03
- Stochastic Oscillator
- TLSI 42.25
- CCIF 80.68
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About CCIF Carlyle Credit Income Fund Shares of Beneficial Interest
Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.